Aprea Therapeutics, Inc. (NASDAQ:APRE – Free Report) – Analysts at Wedbush reduced their FY2028 earnings per share estimates for Aprea Therapeutics in a research report issued to clients and investors on Tuesday, May 14th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of $0.77 per share for the year, down from […]